Back to Journals » Clinical Ophthalmology » Volume 15

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration

Authors Almeida DRP, Ruzicki J, Xu K, Chin EK

Received 24 October 2020

Accepted for publication 22 December 2020

Published 18 January 2021 Volume 2021:15 Pages 189—194

DOI https://doi.org/10.2147/OPTH.S288621

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


David RP Almeida,1 Jessica Ruzicki,2 Kunyong Xu,3 Eric K Chin4

1Vitreoretinal Diseases & Surgery, Erie Retinal Surgery, Erie, PA, USA; 2Department of Ophthalmology, Queen’s University, Kingston, Ontario, Canada; 3Department of Ophthalmology and Visual Sciences, University of Arizona, Arizona, AZ, USA; 4Vitreoretinal Diseases & Surgery, Retina Consultants of Southern California, Redlands, CA, USA; 5Vitreoretinal Diseases & Surgery, Loma Linda University Medical Center, Veterans Affairs Hospital, Loma Linda, CA, USA

Correspondence: David RP Almeida
Erie Retinal Surgery, 300 State Street, Suite 201, Erie, PA 16507, USA
Tel +1 814 456-4241
Fax +1 814 453-3354
Email drpa@pm.me

Purpose: Currently, varying treatment paradigms and different clinical trial constructs preclude cross-trial comparison between different available vascular endothelial growth factor (VEGF) inhibitors. This study aimed to review the evidence and compare the efficacy of anti-VEGF therapies for neovascular age-related macular degeneration (nAMD), and to develop metrics as a means of facilitating standardized comparison between different anti-VEGF agents within the Advanced VitreoRetinal Analytics (AVRA) model.
Methods: The study analyzed key outcomes in clinical trials of bevacizumab, ranibizumab, aflibercept, and brolucizumab, including best corrected visual acuity (BCVA), number of injections, and duration of follow-up (minimum follow-up of 48 weeks).
Results: The AVRA model includes 1) vision recovery velocity (VRV; letters per unit time), which provides a metric of letters gained or lost over time (or the speed of improvement); 2) injection momentum (InjMom; number of injections multiplied by letters per unit time; units of injections•(letters/time)), which is defined as the number of injections multiplied by VRV and describes the quantity of treatment needed to achieve a vision outcome; and 3) vision recovery acceleration (VRA; letters per unit time squared; units of letters/time2), which denotes final VRV minus initial VRV, per unit time, and describes the rate of change in letters gained or lost over time.
Conclusion: AVRA stipulates that the ideal VEGF inhibitor to treat nAMD would have a higher positive VRV (more letters gained per unit time), low InjMom (lower treatment burden requiring fewer interventions for a given visual acuity outcome), and VRA approximating zero (indicating stable vision over time). AVRA allows comparisons across different trials to determine the optimal anti-VEGF agent for the treatment of nAMD.

Keywords: vascular endothelial growth factor inhibitors, neovascular age-related macular degeneration

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]